Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD164 sialomucin-like 2 protein (CD164L2) is a type I transmembrane receptor belonging to the CD164-related protein family, predicted to function at the membrane and in cytoplasmic vesicles[1][7][10]. It is annotated as a host cell receptor for respiratory pathogens[4], but its physiological and pathological roles remain poorly defined. The gene is expressed in humans, with a 174-amino acid protein product. While mutations in CD164L2 have been associated with certain forms of autosomal recessive deafness, there are no well-established links to major therapeutic areas, and no drugs are known to target this protein directly[1][4][7][10]. Information on function, interacting drugs, disease mechanisms, and use as a biomarker remains limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD164 sialomucin-like 2 protein (CD164L2).